Patents by Inventor Joel Menard

Joel Menard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-terminal site selective inhibitors of human angiotensin conversion enzyme (ACE)
    Patent number: 6482797
    Abstract: The invention relates to peptide derivatives that can be used as selective inhibitors of the N-terminal site of human angiotensin-converting enzyme. The derivatives comprise the amino acid sequence with the following formula: -Asp-Phe-&PSgr;(PO2CH2)-Ala-Xaa′-  (I) wherein: &PSgr;(PO2CH2) indicates that the peptide bond (CONH) between Phe and Ala has been replaced by the phosphonic bond PO2CH2, and Xaa′ represents an amino acid residue. They can be used in pharmaceutical formulations, particularly to protect haematopoietic strain cells of patients undergoing aggressive chemotherapy or radiotherapy treatment.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: November 19, 2002
    Assignees: Commissariat A l'Energie Atomique, Institut National de la Sante et de la Recherche Medicale Inserm
    Inventors: Vincent Dive, Joël Cotton, Philippe Cuniasse, Athanasios Yiotakis, Pierre Corvol, Annie Michaud, Marie-Thérèse Chauvet, Joël Menard, Eric Ezan
  • Novel derivatives of pepstatin, their preparation and compositions containing them
    Patent number: 4185096
    Abstract: The novel derivatives of pepstatin have the general formula (I) below in which X, Y and Z, are identical or different, and each represent an amino-acid selected from arginine, glutamic acid, aspartic acid, lysine, histidine and valine, the carboxyl function of the terminal amino-acid being esterifiable. The indices a, b and c are each equal to zero or 1, the sum a+b+c being equal to 1, 2 or 3. The invention also includes the water soluble salts and their preparation, and the compositions containing them. ##STR1## These novel products are particularly useful in the diagnosis and treatment of arterial hypertension due to the action of renine.
    Type: Grant
    Filed: July 31, 1978
    Date of Patent: January 22, 1980
    Assignee: Agence Nationale de Valorisation de la Recherche (ANVAR)
    Inventors: Bertrand Castro, Joel Menard, Genevieve Evin, Pierre Corvol